Aquestive Therapeutics Inc.
Find Ratings ReportsAQUESTIVE THERAPETC INC's gross profit margin for the third quarter of its fiscal year 2023 is essentially unchanged when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the subsector, the net income growth has not. AQUESTIVE THERAPETC INC has average liquidity. Currently, the Quick Ratio is 1.39 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 4.53% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY23 | Q3 FY22 |
---|---|---|
Net Sales ($mil) | 13.0 | 11.46 |
EBITDA ($mil) | -2.11 | -8.26 |
EBIT ($mil) | -2.38 | -8.85 |
Net Income ($mil) | -2.04 | -12.54 |
Balance Sheet | Q3 FY23 | Q3 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 24.92 | 18.65 |
Total Assets ($mil) | 59.45 | 51.85 |
Total Debt ($mil) | 45.04 | 55.09 |
Equity ($mil) | -102.93 | -107.82 |
Profitability | Q3 FY23 | Q3 FY22 |
---|---|---|
Gross Profit Margin | 64.74 | 63.66 |
EBITDA Margin | -16.25 | -72.03 |
Operating Margin | -18.28 | -77.23 |
Sales Turnover | 0.81 | 0.93 |
Return on Assets | -20.37 | -136.95 |
Return on Equity | 0.0 | 0.0 |
Debt | Q3 FY23 | Q3 FY22 |
---|---|---|
Current Ratio | 1.76 | 1.04 |
Debt/Capital | -0.78 | -1.04 |
Interest Expense | 1.31 | 3.69 |
Interest Coverage | -1.81 | -2.4 |
Share Data | Q3 FY23 | Q3 FY22 |
---|---|---|
Shares outstanding (mil) | 66.74 | 53.85 |
Div / share | 0.0 | 0.0 |
EPS | -0.03 | -0.23 |
Book value / share | -1.54 | -2.0 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 1461195.0 | 328937.0 |
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AQST NM | Peers 85.83 | AQST 37.90 | Peers 38.76 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. AQST's P/E is negative making this valuation measure meaningless. |
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. AQST is trading at a valuation on par to its peers. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
AQST NM | Peers 18.08 | AQST NA | Peers 1.16 | |||||||||||||||||||||
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. AQST's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
AQST NM | Peers 19.07 | AQST 84.67 | Peers 12.58 | |||||||||||||||||||||
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. AQST's P/B is negative making this valuation measure meaningless. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. AQST is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
AQST 7.29 | Peers 84.44 | AQST -0.04 | Peers 42.35 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. AQST is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. AQST significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||